Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement receptor type 1 (CR1)
- Target
- CR1
- Molecular classification
- Regulator of Complement Activation, Membrane glycoprotein
01
Overview
Complement receptor type 1 (CR1), also known as C3b/C4b receptor or CD35, is a membrane glycoprotein that plays a crucial role in the regulation of the complement system. It acts as a negative regulator by binding activated complement fragments C3b and C4b, accelerating the decay of complement convertases and serving as a cofactor for Factor I-mediated inactivation of C3b and C4b. CR1 is expressed on various immune cells and erythrocytes, facilitating immune complex clearance and preventing tissue deposition. Decreased expression or mutations in CR1 are associated with several autoimmune and inflammatory diseases, including systemic lupus erythematosus and Alzheimer's disease. A soluble form of CR1 (sCR1) has been developed as a therapeutic agent to inhibit unwanted complement activation.
- Other names
- C3b/C4b receptorCD35sCR1
02
Mechanism of action
Inhibition of complement activation
03
Biological functions
Regulation of complement cascadeDecay acceleration of complement convertasesCofactor activity for Factor IImmune complex clearanceB-cell differentiation
04
Disease associations
Systemic lupus erythematosusMesangiocapillary glomerulonephritisSarcoidosisGallbladder carcinomaAlzheimer's diseaseHIV infectionMalaria
05
Safety considerations
Potential for immune suppressionOff-target effects of sCR1
06
Interacting drugs
sCR1 (recombinant)
07
Biomarkers
CR1 expression levels in SLECR1 alleles in Alzheimer's diseaseKnops blood group antigens
Beyond the preview
Go deeper on Complement receptor type 1 (CR1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Complement receptor type 1 (CR1).